Talk / Overview

Bringing any new drug to the market takes years, hundreds of millions (to billions) of dollars in research and there's a risk at every development phase that the drug fails to meet the objectives, either due to a bad study design, difficulty to find patients to be enrolled, issues with how the data points are analyzed or inappropriate efficacy metrics/trial endpoints. This is a problem for patients who need the therapies and for pharma developing drugs, because enabling the right decisions is healthcare is expensive and time consuming. In this talk we will show a few examples of how regulatory-grade AI biomarers are redefining the industry standards to enable the right decision sooner via improved management and oversight of clinical studies and real time monitoring and analysis of data.

Talk / Speakers

Carlos Ciller

CEO & Co-founder, RetinAI

Talk / Highlights

Enabling the Right Decisions Sooner in Healthcare with AI

With Carlos CillerPublished April 27, 2022

AMLD / Global partners